Cargando…

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC

INTRODUCTION: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment. To understand the relationship between tissue-based versus blood-based testing, we retrospectively i...

Descripción completa

Detalles Bibliográficos
Autores principales: Noé, Johannes, Bordogna, Walter, Archer, Venice, Smoljanovic, Vlatka, Hilton, Magalie, Woodhouse, Ryan, Mocci, Simonetta, Gadgeel, Shirish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218556/
https://www.ncbi.nlm.nih.gov/pubmed/35756755
http://dx.doi.org/10.1016/j.jtocrr.2022.100341
_version_ 1784731917874102272
author Noé, Johannes
Bordogna, Walter
Archer, Venice
Smoljanovic, Vlatka
Hilton, Magalie
Woodhouse, Ryan
Mocci, Simonetta
Gadgeel, Shirish M.
author_facet Noé, Johannes
Bordogna, Walter
Archer, Venice
Smoljanovic, Vlatka
Hilton, Magalie
Woodhouse, Ryan
Mocci, Simonetta
Gadgeel, Shirish M.
author_sort Noé, Johannes
collection PubMed
description INTRODUCTION: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment. To understand the relationship between tissue-based versus blood-based testing, we retrospectively investigated concordance between VENTANA ALK (D5F3) CDx immunohistochemistry and the FoundationACT (FACT; Foundation Medicine, Inc.) plasma assay, and compared clinical efficacy between phase 3 ALEX study subpopulations. METHODS: Patients with advanced ALK-positive (by immunohistochemistry) NSCLC were randomized 1:1 to alectinib 600 mg or crizotinib 250 mg, twice daily. Assessable baseline plasma samples were analyzed for ALK positivity by FACT; positive percent agreement with immunohistochemistry was evaluated. Progression-free survival (PFS), duration of response, and objective response rate were compared between intention-to-treat (ITT) and biomarker-evaluable populations, and plasma ALK-positive and plasma ALK-negative subpopulations. RESULTS: In the ITT population (303 patients; alectinib, 152; crizotinib, 151), all patients had ALK-positive tumors by immunohistochemistry. In the biomarker-evaluable population (149 patients; alectinib, 76; crizotinib, 73), 105 had plasma ALK-positive and 44 had plasma ALK-negative tumors. Positive percent agreement between immunohistochemistry and FACT was 70.5% (105 of 149; 95% confidence interval: 62.5–77.7). Baseline characteristics were generally balanced, with some exceptions, notably tumor burden. Median PFS in plasma ALK-positive and ALK-negative patients was 22.4 months and not estimable with alectinib and 7.3 months and 12.9 months with crizotinib, respectively; median duration of response was 25.9 months and not estimable with alectinib and 5.6 months and 11.5 months with crizotinib, respectively. CONCLUSIONS: Reasonable concordance between FACT and immunohistochemistry was observed; both methods are valuable in identifying ALK-positive patients, separately or concurrently. Alectinib was found to have superior PFS in the plasma ALK-positive population, as in the ITT population.
format Online
Article
Text
id pubmed-9218556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92185562022-06-24 Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC Noé, Johannes Bordogna, Walter Archer, Venice Smoljanovic, Vlatka Hilton, Magalie Woodhouse, Ryan Mocci, Simonetta Gadgeel, Shirish M. JTO Clin Res Rep Original Article INTRODUCTION: The Blood First Assay Screening Trial revealed the clinical applicability of blood-based next-generation sequencing to identify patients with ALK-positive NSCLC for alectinib treatment. To understand the relationship between tissue-based versus blood-based testing, we retrospectively investigated concordance between VENTANA ALK (D5F3) CDx immunohistochemistry and the FoundationACT (FACT; Foundation Medicine, Inc.) plasma assay, and compared clinical efficacy between phase 3 ALEX study subpopulations. METHODS: Patients with advanced ALK-positive (by immunohistochemistry) NSCLC were randomized 1:1 to alectinib 600 mg or crizotinib 250 mg, twice daily. Assessable baseline plasma samples were analyzed for ALK positivity by FACT; positive percent agreement with immunohistochemistry was evaluated. Progression-free survival (PFS), duration of response, and objective response rate were compared between intention-to-treat (ITT) and biomarker-evaluable populations, and plasma ALK-positive and plasma ALK-negative subpopulations. RESULTS: In the ITT population (303 patients; alectinib, 152; crizotinib, 151), all patients had ALK-positive tumors by immunohistochemistry. In the biomarker-evaluable population (149 patients; alectinib, 76; crizotinib, 73), 105 had plasma ALK-positive and 44 had plasma ALK-negative tumors. Positive percent agreement between immunohistochemistry and FACT was 70.5% (105 of 149; 95% confidence interval: 62.5–77.7). Baseline characteristics were generally balanced, with some exceptions, notably tumor burden. Median PFS in plasma ALK-positive and ALK-negative patients was 22.4 months and not estimable with alectinib and 7.3 months and 12.9 months with crizotinib, respectively; median duration of response was 25.9 months and not estimable with alectinib and 5.6 months and 11.5 months with crizotinib, respectively. CONCLUSIONS: Reasonable concordance between FACT and immunohistochemistry was observed; both methods are valuable in identifying ALK-positive patients, separately or concurrently. Alectinib was found to have superior PFS in the plasma ALK-positive population, as in the ITT population. Elsevier 2022-05-18 /pmc/articles/PMC9218556/ /pubmed/35756755 http://dx.doi.org/10.1016/j.jtocrr.2022.100341 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Noé, Johannes
Bordogna, Walter
Archer, Venice
Smoljanovic, Vlatka
Hilton, Magalie
Woodhouse, Ryan
Mocci, Simonetta
Gadgeel, Shirish M.
Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title_full Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title_fullStr Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title_full_unstemmed Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title_short Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
title_sort concordance between tissue alk detection by immunohistochemistry and plasma alk detection by next-generation sequencing in the randomized phase 3 alex study in patients with treatment-naive advanced alk-positive nsclc
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218556/
https://www.ncbi.nlm.nih.gov/pubmed/35756755
http://dx.doi.org/10.1016/j.jtocrr.2022.100341
work_keys_str_mv AT noejohannes concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT bordognawalter concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT archervenice concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT smoljanovicvlatka concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT hiltonmagalie concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT woodhouseryan concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT moccisimonetta concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc
AT gadgeelshirishm concordancebetweentissuealkdetectionbyimmunohistochemistryandplasmaalkdetectionbynextgenerationsequencingintherandomizedphase3alexstudyinpatientswithtreatmentnaiveadvancedalkpositivensclc